Stocktoria
Aardvark Therapeutics, Inc. AARD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-02-13
Chart by TradingView
1/9
Piotroski F — financial health
9.47
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Revenue | $0 | — |
| Operating income | -$62.7M | -$22.8M |
| Net income | -$57.6M | -$20.6M |
| Operating cash flow | -$54.2M | -$18.1M |
| Free cash flow | -$54.3M | -$18.2M |
| Total assets | $117.2M | $77.5M |
| Total liabilities | $10.5M | $5.4M |
| Shareholders' equity | $106.6M | -$54.6M |
| Ratios | ||
| Return on assets | -49.1% | -26.6% |
| Return on equity | -54.0% | 37.7% |
| Current ratio | 10.61 | 15.05 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 70,792 | $266,886 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 9.47 (safe)
- Working capital / assets 0.865
- Retained earnings / assets -0.989
- EBIT / assets -0.535
- Equity / liabilities 10.109
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001774857 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.